Full-Time
SAP Integration Lead
Support Services Organization
Posted on 9/4/2025
Pfizer
10,001+ employees
Biopharmaceutical company develops medicines and vaccines
No salary listed
Chennai, Tamil Nadu, India
In Person
 IT & Security (2) |
|---|
| , |
- BS/MS Degree in Information Management, Computer Science, Engineering or related area
- 5+ years of experience in developing Interface objects using technologies like ABAP ALE, EDI, IDOC, RFC, BAPIs
- 5+ years of experience working with SAP Cloud based integration technologies, such as SAP Cloud Integration, API/M, SAP DI
- Strong knowledge of SAP Interface architecture, components, functions, and features such as XML, JSON and WSDL expertise
- Project management knowledge & skills
- Ability to function effectively in a matrix model as well as team environment
- Excellent communication, collaboration, and problem-solving skills
- At least 1-3 full cycle SAP implementation experience
- Understanding off-site/offshore and remote development methodology is needed
- Lead and support SAP Interface development activities for SAP Manufacturing, Warehouse Management functions
- Support integration projects through various phases from gathering business requirements to go-live and post-implementation support
- Design, Build and support end-to-end functional designs for interfaces using EDI (ANSI and EDIFACT standards), SAP IDOCs, APIs, Web services and SFTP
- Collaborate with other middleware teams in the landscape that manage Gentran Integration Server (GIS), Middleware tools, Secure FTP, Extract Transform and Load (ETL)
- Suggest improvements to current operational procedures within the integration environment
- Test and develop SAP OData services, APIs, CPI iFlows and APIM components as part of the development team using agile methodologies
- Collaborate with both internal and external partners to Develop customized SAP interfaces
- Support and maintain existing interfaces
- Review and revise technical designs in Integration design Documents to meet Integration project requirements
- Provide technical and functional guidance to internal Pfizer clients
- Coordination and execution of integration solutions for new initiative deployments. Solution deployments may cross many applications and technologies including SAP and non-SAP systems, as well as emerging technologies
- Extensive knowledge of SAP data model
- Proficiency in implementing integration flows (iFlows) using various adapters, such as SFTP, OData, SOAP, HTTPS, Mail, JDBC, IDoc, Process Call, JMS and Mail
- 3+ years of working experience in WM, PP, MM modules (areas MRP, Process Orders, Planned Orders, Material documents, Goods Receipts, Goods Issues, Transfer Orders, Transfer Requirements, Cycle Counts etc.)
- Development experience in using ABAP Objects, Webdynpros, BDC, User-exits, BAdIs, Reports is a plus
- Working with SAP Enhancements, Dialog Programming is a plus
- Proficiency in Microsoft Project Office Suite (Word, Power Point, Excel)
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
Simplify's Take
What believers are saying
- Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
- VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
- ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.
What critics are saying
- Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
- Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
- Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.
What makes Pfizer unique
- Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
- Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
- Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Company News
ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich
Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.
Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.
Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.
Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.